miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2

• Main Authors: Ling Ye (Author), Tao Jiang (Author), Huanzhang Shao (Author), Lin Zhong (Author), Zhaowen Wang (Author), Yuan Liu (Author), Huamei Tang (Author), Bingyu Qin (Author), Xiaoqing Zhang (Author), Junwei Fan (Author)
• Format: Book
• Published: Elsevier, 2017-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

5-Fluorouracil (5FU)-based adjuvant therapy is the first-line therapy for treating stage II and III colon cancer after surgery. However, its therapeutic efficacy is limited because of chemoresistance, especially in deficient mismatch repair (dMMR) colon cancer. Here, we first used laser capture micr...